Arcus Biosciences, Inc. RCUS
Set alert
17.85 USD -0.34 -1.87%
At close · Nov 2
17.85 0.00 0.00%
After hours · Nov 2, 4:01 PM ET
17.76 Day range 18.49
17.43 52-week range 31.74
- YTD
- -25.09%
- 1 year
- -9.48%
- Open
- 18.23
- Prev close
- 18.19
- Mkt cap
- 2.25B
- Vol
- 1.38M
- Avg vol
- 1.81M
- EPS
- -3.84
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 17.76
- High
- 18.49
- Forward P/E
- -5.72
- Beta
- 1.09
- Short ratio
- 8.16
- Inst. own
- 66.27%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 24.98
- 200-d avg
- 24.67
- 1y target
- 41.00
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 41.00 +129.7% upside
Now 17.85
- Target (low)
- 23.00
- Target (mean)
- 41.00
- Target (high)
- 50.00
Ratings (0m) 15 13 buy · 2 hold · 0 sell
- Strong buy1
- Buy12
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 15
- 1 month ago 13
- 2 months ago 13
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.89254 | -1.00 – -0.84 | -1.27 | +29.7% | 8.27M | -68.2% | 9 |
| Next quarter | -0.84183 | -0.96 – -0.75 | -0.89 | +5.4% | 5.99M | -81.8% | 9 |
| Current year | -3.52 | -4.35 – -3.10 | -3.29 | -6.9% | 73.15M | -70.4% | 9 |
| Next year | -3.12 | -4.50 – -2.16 | -3.52 | +11.2% | 56.52M | -22.7% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | Citigroup | Maintained | Buy | Buy |
| Oct 21, 2026 | Truist Securities | Maintained | Buy | Buy |
| Oct 21, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Oct 16, 2026 | William Blair | Initiated | — | Outperform |
| Oct 14, 2026 | JP Morgan | Initiated | — | Overweight |
| Sep 30, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Sep 16, 2026 | TD Cowen | Initiated | — | Buy |
| Sep 8, 2026 | Truist Securities | Reiterated | Buy | Buy |
| Aug 6, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Aug 6, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jul 20, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 4, 2026 | LifeSci Capital | Initiated | — | Outperform |
| May 11, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| May 7, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Apr 2, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Mar 5, 2026 | Citigroup | Maintained | Buy | Buy |
| Mar 2, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Mar 2, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 12, 2026 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Jan 13, 2026 | Goldman Sachs | Upgrade | Neutral | Buy |
| Jan 8, 2026 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Dec 12, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 28, 2025 | B of A Securities | Maintained | Neutral | Neutral |
| Oct 30, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| Oct 29, 2025 | Citigroup | Maintained | Buy | Buy |
| Oct 29, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 20, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Oct 13, 2025 | Citigroup | Maintained | Buy | Buy |
| Oct 7, 2025 | Truist Securities | Reiterated | Buy | Buy |
| Aug 7, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |